Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Filings indexed 912 across all filing types
Latest filing 2025-08-06 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Press Release on Q1 26 Un-audited Financial Results
Regulatory Filings
2025-08-06 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated August 6, 2025, announcing the unaudited financial results for the quarter ended June 30, 2025 (Q1FY26). It contains consolidated financial highlights including revenue, EBITDA, and PAT figures, along with commentary from a company director on performance and future plans. The document is approximately 13,834 characters long, which is substantial and contains actual financial data and analysis for the quarter. It is not a full annual report but a quarterly financial announcement with detailed financial results and management commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2025-08-06 English
Change in Director(s)
Regulatory Filings
2025-08-04 English
Appointment
Regulatory Filings
2025-08-04 English
Appointment of Mr. Chandran Krishnamoorthy has been appointed as a WTD of the Company to hold the office for a term of 5 years.
Regulatory Filings
2025-08-04 English
Appointment of Mr. Chandran Krishnamoorthy as a Whole time director of the Company for a tenure of 5 years subject to the approval of shareholders.
Regulatory Filings
2025-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.